Stefan Feiten1, Geothy Chakupurakal2, Hans Peter Feustel3, Michael Maasberg4, Burkhard Otremba5, Peter Ehscheidt6, Manfred Hensel7, Richard Hansen8, Rudolf Weide2. 1. Institut für Versorgungsforschung in der Onkologie, Koblenz, Germany. s.feiten@invo-koblenz.de. 2. Praxisklinik für Hämatologie und Onkologie, Koblenz, Germany. 3. Onkologische Schwerpunktpraxis, Speyer, Germany. 4. Onkologische Gemeinschaftspraxis, Mayen, Germany. 5. Onkologische Praxis, Oldenburg/Delmenhorst, Germany. 6. Onkologische Praxis Dr. Ehscheidt, Neuwied, Germany. 7. Mannheimer Onkologie Praxis, Mannheim, Germany. 8. Onkologische Schwerpunktpraxis, Kaiserslautern, Germany.
Abstract
PURPOSE: Immunomodulatory drugs (IMIDS) have changed the treatment and outcome of patients suffering from multiple myeloma. However, with the oral administration adherence becomes an issue. Since there is no "gold standard" in measuring adherence, we assessed the adherence of myeloma patients with the help of different data sources. METHODS: All patients who have been receiving IMIDS for at least 3 months were eligible. Computer assisted personal interviews of patients and, if possible, their caregivers were carried out. Attending oncologists evaluated the patient's adherence with the help of a standardized questionnaire. In addition, a retrospective analysis of prescription data was conducted. All data were analyzed statistically using SPSS. RESULTS: One hundred myeloma patients, 35% female, 65% male, with a median age of 70 years (37-86) were interviewed. Prescription data could be evaluated in terms of adherence in 78 patients (78%), 56 caregivers could be questioned (56%). Ninety-seven percent of patients rated themselves as adherent in taking IMIDS. Data from treating oncologists, caregivers and prescriptions supported this result. IMID therapies were rated as very effective and significant, toxicities were acceptable and dosing regimens simple/uncomplicated. CONCLUSIONS: Myeloma patients seem to be highly adherent to IMID treatments.
PURPOSE: Immunomodulatory drugs (IMIDS) have changed the treatment and outcome of patients suffering from multiple myeloma. However, with the oral administration adherence becomes an issue. Since there is no "gold standard" in measuring adherence, we assessed the adherence of myelomapatients with the help of different data sources. METHODS: All patients who have been receiving IMIDS for at least 3 months were eligible. Computer assisted personal interviews of patients and, if possible, their caregivers were carried out. Attending oncologists evaluated the patient's adherence with the help of a standardized questionnaire. In addition, a retrospective analysis of prescription data was conducted. All data were analyzed statistically using SPSS. RESULTS: One hundred myelomapatients, 35% female, 65% male, with a median age of 70 years (37-86) were interviewed. Prescription data could be evaluated in terms of adherence in 78 patients (78%), 56 caregivers could be questioned (56%). Ninety-seven percent of patients rated themselves as adherent in taking IMIDS. Data from treating oncologists, caregivers and prescriptions supported this result. IMID therapies were rated as very effective and significant, toxicities were acceptable and dosing regimens simple/uncomplicated. CONCLUSIONS:Myelomapatients seem to be highly adherent to IMID treatments.
Authors: Ralph Winterhalder; Pierre Hoesli; Geoffrey Delmore; Stefanie Pederiva; Albéric Bressoud; Frank Hermann; Roger von Moos Journal: Oncology Date: 2011-05-23 Impact factor: 2.935
Authors: Lonneke Timmers; Christel C L M Boons; Femke Kropff; Peter M van de Ven; Eleonora L Swart; Egbert F Smit; Sonja Zweegman; Judith R Kroep; Johanna N H Timmer-Bonte; Epie Boven; Jacqueline G Hugtenburg Journal: Acta Oncol Date: 2013-11-22 Impact factor: 4.089
Authors: Stefan Feiten; Rudolf Weide; Vera Friesenhahn; Jochen Heymanns; Kristina Kleboth; Hubert Köppler; Christoph van Roye; Jörg Thomalla Journal: Springerplus Date: 2016-03-03
Authors: Stefan Feiten; Geothy Chakupurakal; Hans Peter Feustel; Michael Maasberg; Burkhard Otremba; Peter Ehscheidt; Manfred Hensel; Richard Hansen; Rudolf Weide Journal: Support Care Cancer Date: 2019-11-08 Impact factor: 3.603